Neoplasms
Conditions
Keywords
Immunosuppression
Brief summary
The aim of the project is to improve the overall treatment and outcome of renal, pancreas or liver transplanted patients who have encountered a malignancy by a structured treatment program for diagnosis and treatment of the malignancy, optimization of the immunosuppressive treatment, follow-up and evaluation of the program.
Interventions
OTHERReferral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection
DRUGSwitch from calcineurin inhibitor to an mTOR inhibitor
Sponsors
Uppsala University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients willing and capable of giving written informed consent of participation in the project * Patients with a previous diagnosed or presently diagnosed or reoccurrence of a malignancy (other then basal cell carcinoma)
Exclusion criteria
* Patients with a primary liver cancer as cause of the transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient survival | 12 months, 2 years, 3 years | After inclusion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Graft survival | 12 months, 2 years, 3 years | After inclusion |
| ImmuKnow Assay value | 12 months | — |
| Tumour progression/regression/reoccurrence | 12 months, 2 years, 3 years | — |
| Maintained switch of immunosuppression from calcineurin inhibitor to mTOR inhibitor | 3 years | — |
| Kidney function | 12 months, 2 years, 3 years | Creatinine measure |
Countries
Sweden
Outcome results
None listed